News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vical Incorporated (VICL) Reviews Herpes Simplex Vaccine Progress at 2nd International Conference and Exhibition on Cell & Gene Therapy


10/24/2013 9:42:26 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ORLANDO, Fla., Oct. 24, 2013 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that a review of the company's progress toward clinical testing of its Vaxfectin®-formulated therapeutic vaccine against herpes simplex virus type 2 (HSV-2) will be presented at the 2nd International Conference and Exhibition on Cell & Gene Therapy, held in Orlando, Florida. Published results from preclinical therapeutic vaccine studies demonstrated significant reduction in recurrence of viral lesions and viral shedding in HSV-2 infected guinea pigs. A Phase 1/2 clinical trial of the vaccine is expected to begin in late 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES